Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Deferred Tax: 2009-2012

  • Northwest Biotherapeutics' Long-Term Deferred Tax rose 70.20% to $87.6 million in Q4 2012 from the same period last year, while for Dec 2012 it was $87.6 million, marking a year-over-year increase of 70.20%. This contributed to the annual value of $87.6 million for FY2012, which is 70.20% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Long-Term Deferred Tax of $87.6 million as of Q4 2012, which was up 70.20% from $51.5 million recorded in Q4 2011.
  • In the past 5 years, Northwest Biotherapeutics' Long-Term Deferred Tax registered a high of $87.6 million during Q4 2012, and its lowest value of $39.4 million during Q4 2009.
  • Its 3-year average for Long-Term Deferred Tax is $61.0 million, with a median of $51.5 million in 2011.
  • Data for Northwest Biotherapeutics' Long-Term Deferred Tax shows a peak YoY surged of 70.20% (in 2012) over the last 5 years.
  • Over the past 4 years, Northwest Biotherapeutics' Long-Term Deferred Tax (Quarterly) stood at $39.4 million in 2009, then climbed by 11.79% to $44.0 million in 2010, then climbed by 16.94% to $51.5 million in 2011, then soared by 70.20% to $87.6 million in 2012.
  • Its last three reported values are $87.6 million in Q4 2012, $51.5 million for Q4 2011, and $44.0 million during Q4 2010.